183 related articles for article (PubMed ID: 36383907)
1. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.
Martiniova L; Zielinski RJ; Lin M; DePalatis L; Ravizzini GC
Cancer J; 2022 Nov-Dec 01; 28(6):446-453. PubMed ID: 36383907
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody based radiopharmaceuticals for imaging and therapy.
Lin M; Paolillo V; Le DB; Macapinlac H; Ravizzini GC
Curr Probl Cancer; 2021 Oct; 45(5):100796. PubMed ID: 34657748
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
4. Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.
Abusalem M; Martiniova L; Soebianto S; DePalatis L; Ravizzini G
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760506
[TBL] [Abstract][Full Text] [Related]
5. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
6. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
7. Application of Immuno-PET in Antibody-Drug Conjugate Development.
Carmon KS; Azhdarinia A
Mol Imaging; 2018; 17():1536012118801223. PubMed ID: 30370812
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
9. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
12. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
14. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
Hasan MM; Laws M; Jin P; Rahman KM
Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.
Saini S; Gulati N; Awasthi R; Arora V; Singh SK; Kumar S; Gupta G; Dua K; Pahwa R; Dureja H
Curr Drug Deliv; 2024; 21(7):993-1009. PubMed ID: 37519200
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
18. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]